Sentinel lymph node biopsy in melanoma: beyond histologic factors

Area of Science:

• Oncology
• Surgical Pathology

Background:

• Sentinel lymph node (SLN) biopsy is a key procedure in cutaneous melanoma management.
• Current guidelines recommend SLN biopsy for tumors >1 mm and selectively for tumors 0.8-1 mm.
• The prognostic and therapeutic utility of SLN biopsy for tumors <1 mm remains unclear.

Purpose of the Study:

• To review recent advancements in predicting sentinel lymph node positivity in melanoma.
• To discuss the potential for omitting SLN biopsy in select patient groups based on new data.

Main Methods:

• Review of recent studies evaluating patient populations, histopathologic characteristics, and gene expression profiling.
• Analysis of data to improve prediction of SLN positivity.

Main Results:

• Emerging data offer insights into predicting SLN positivity.
• Clinicopathological characteristics may help identify patients for whom SLN biopsy omission is appropriate.

Conclusions:

• Refined prediction of SLN positivity can guide clinical decision-making.
• Further research is ongoing to optimize SLN biopsy utility in melanoma management.